# Prop. 64 at 10: Why the Illicit Cannabis Market Still Dominates in California > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/california-cannabis-legalization-challenges/ > **Published:** 2026-04-17T10:02:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:19:58-04:00 > **Clinical Summary:** Explore California cannabis legalization challenges and why the illicit market still dominates after 10 years, impacting patient safety and regulation. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Product SafetyRegulation[Patient Education](https://cedclinic.com/medical-cannabis-patient-education-basics/)[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Quality Control Why This Matters California’s persistent illicit market dominance affects patient safety through unregulated product quality, dosing inconsistency, and contamination risks. Clinicians counseling cannabis patients must understand that legal access doesn’t guarantee patients are using regulated products. Clinical Summary Ten years after California’s adult-use legalization, illicit cannabis sales continue to exceed legal market volume due to high taxation, regulatory complexity, and price disparities. This market fragmentation creates a dual-track system where patients may access both regulated medical products and unregulated recreational products. The persistence of illicit markets reflects implementation challenges rather than legalization failure, with implications for product quality control, laboratory testing, and patient safety protocols. Dr. Caplan’s Take “I tell patients that a legal framework doesn’t automatically mean they’re getting regulated products — price and convenience often drive purchasing decisions toward untested cannabis that may contain pesticides, heavy metals, or incorrect potency labeling.” Clinical Perspective 🧠 Clinicians should routinely ask patients about their cannabis sources and emphasize the importance of laboratory-tested products, especially for medical use. Consider discussing cost barriers to legal access and help patients understand the safety trade-offs between regulated and unregulated products. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Prop.%2064%20at%2010%3A%20Why%20the%20illicit%20cannabis%20market%20still%20dominates%20in%20California%20%40drcaplan&url=https%3A//www.mercurynews.com/2026/04/16/prop-64-at-10-why-the-illicit-cannabis-market-still-dominates/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.mercurynews.com/2026/04/16/prop-64-at-10-why-the-illicit-cannabis-market-still-dominates/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Prop.%2064%20at%2010%3A%20Why%20the%20illicit%20cannabis%20market%20still%20dominates%20in%20California%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.mercurynews.com/2026/04/16/prop-64-at-10-why-the-illicit-cannabis-market-still-dominates/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.mercurynews.com/2026/04/16/prop-64-at-10-why-the-illicit-cannabis-market-still-dominates/](https://www.mercurynews.com/2026/04/16/prop-64-at-10-why-the-illicit-cannabis-market-still-dominates/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What are the main topics covered in this cannabis-related article?](#What_are_the_main_topics_covered_in_this_cannabis-related_article) - [Who is the target audience for this cannabis news update?](#Who_is_the_target_audience_for_this_cannabis_news_update) - [Why is this cannabis news considered noteworthy for clinicians?](#Why_is_this_cannabis_news_considered_noteworthy_for_clinicians) - [What type of cannabis information does this update provide?](#What_type_of_cannabis_information_does_this_update_provide) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the findings or policy developments are emerging and worth monitoring closely by healthcare professionals. #### What are the main topics covered in this cannabis-related article? The article focuses on four key areas: product safety, regulation, [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/), and [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). These topics indicate comprehensive coverage of important clinical and regulatory aspects of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). #### Who is the target audience for this cannabis news update? This update is primarily intended for healthcare professionals, particularly those working in clinical settings. The CED Clinic designation suggests it’s relevant for clinicians who need to stay informed about cannabis-related developments. #### Why is this cannabis news considered noteworthy for clinicians? The “Notable Clinical Interest” classification indicates this contains emerging findings or policy developments that could impact [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). Clinicians should monitor these developments as they may influence treatment decisions or patient counseling. #### What type of cannabis information does this update provide? This appears to be a clinical education update that combines product safety information with regulatory changes and patient education guidance. It provides a comprehensive overview of current developments in the medical cannabis field. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [California Marks 10 Years Of Cannabis Legalization Amid Illegal Market Struggle – Forbes](https://cedclinic.com/california-cannabis-legalization-10-years-market-safety/) An in-depth look at California's decade-long journey with [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and the ongoing challenges posed by the illegal market. [Read More](https://cedclinic.com/california-cannabis-legalization-10-years-market-safety/) [Cannabis Sales Plummet as Regulators Crack Down on Booming Industry](https://cedclinic.com/cannabis-market-disruption-regulatory-crackdown/) Explore how regulatory actions are impacting cannabis sales and the industry's response to enforcement pressures. [Learn More](https://cedclinic.com/cannabis-market-disruption-regulatory-crackdown/) [Why the Future of Marijuana Legalization Remains Hazy Despite High Public Support](https://cedclinic.com/regulatory-uncertainty-cannabis-research-challenges/) Analysis of the complexities and uncertainties surrounding marijuana legalization despite widespread public approval. [Discover Insights](https://cedclinic.com/regulatory-uncertainty-cannabis-research-challenges/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).